Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eye (Lond) ; 23(1): 73-8, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17917683

RESUMO

PURPOSE: To determine the incidence of glaucomatous progression at mean intraocular pressure (IOP) levels in patients with ocular hypertension (OHT). METHODS: A retrospective, multicentre, cohort analysis of 230 OHT patients with 5 years of follow-up evaluated for risk factors associated with progressive optic disc and visual field loss to determine the incidence of glaucomatous progression. RESULTS: Forty percent of patients with IOPs > or = 24 mmHg, 18% of patients with IOPs of 21-23 mmHg, 11% of patients with IOPs with 18-20 mmHg, and 3% of patients with IOPs of < or = 17 mmHg progressed to glaucoma. The mean IOP was 19.8+/-2.4 mmHg in the stable group and 21.7+/-2.6 mmHg in the progressed group (P=0.0004). The highest average peak IOP was 23.4+/-4.0 mmHg in the stable group and 25.2+/-3.1 mmHg in the progressed group (P=0.006). Based on the pachymetry values for central corneal thickness, patients with thinner corneas more often progressed to glaucoma (P<0.0001). A multivariant regression analysis to determine risk factors for progression was positive primarily for higher peak IOPs, older age, male gender, argon laser trabeculoplasty, visual acuity > or = 20/50, and no topical medical therapy or beta-blocker therapy prior to the study. CONCLUSIONS: IOP reduction within the normal range over 5 years of follow-up reduces the chance of progression to primary open-angle glaucoma in OHT patients.


Assuntos
Córnea/anatomia & histologia , Pressão Intraocular/fisiologia , Hipertensão Ocular/fisiopatologia , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Idoso , Progressão da Doença , Feminino , Glaucoma/fisiopatologia , Glaucoma/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/patologia , Análise de Regressão , Estudos Retrospectivos , Fatores de Risco , Trabeculectomia/estatística & dados numéricos , Acuidade Visual/fisiologia , Adulto Jovem
2.
J Hazard Mater ; 136(1): 137-43, 2006 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-16386368

RESUMO

This article utilizes a Monte Carlo stochastic framework to investigate the influence on the mean and variance of the predicted mean pressure head profile of statistical assumptions regarding the parameters that enter the mathematical description of the problem of infiltration in unsaturated, heterogeneous layers. The parameters are treated as random functions with an exponential auto-covariance function expressing their spatial continuity. Four different truncated distributions are taken to describe the parameters according to field observations and various phases of site characterization campaigns. The exponential distribution is seen to produce the largest (in absolute value) mean and variance in the pressure head profile. For all distributions the variance in pressure head increases with increasing mean pressure. A second topic of this article is to investigate, the relative importance of each parameter, in terms of the mean and the variance of the predicted pressure. For uniformly or triangularly distributed parameters the saturated hydraulic conductivity appears to dominate the mean-behavior and the uncertainty in the system's solution. For lognormally or exponentially distributed parameters another parameter, the van Genuchten pore-size distribution index, is the dominant factor.


Assuntos
Solo/análise , Incerteza , Pressão , Processos Estocásticos
3.
Eye (Lond) ; 18(9): 893-9, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15002024

RESUMO

AIMS: To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vs latanoprost in subjects with exfoliation glaucoma (XFG). METHODS: A 3-month prospective, single-masked, active-controlled, parallel comparison performed in six centres in Greece that randomized subjects in a 1 : 1 ratio to either latanoprost in the evening (2000 hours) and placebo in the morning (0800 hours), or timolol twice daily (0800 and 2000 hours). RESULTS: In all, 103 subjects completed the study. After 3 months of chronic dosing, the latanoprost group exhibited a trend to a greater diurnal IOP reduction from an untreated baseline (24.9+/-3.2-17.4+/-2.9) compared with timolol (24.7+/-2.8-18.3+/-1.9 mmHg) (P=0.07). Latanoprost showed a significantly greater IOP reduction at 0800 hours (-8.5 vs -6.0 mm Hg for timolol, P<0.0001) whereas no difference was observed between the two medications at 1000, 1400, and 2000 hours after a Bonferroni Correction. In addition, latanoprost demonstrated a narrower range of diurnal IOP (2.4) than timolol (3.2 mmHg)(P=0.0017). Safety was similar between groups, except there was more conjunctival hyperaemia with latanoprost (n=8) than timolol (n=1)(P=0.01). CONCLUSIONS: This study suggests that latanoprost provides a statistically lower 08:00-hour IOP and better range of IOP than timolol in the treatment of XFG glaucoma.


Assuntos
Anti-Hipertensivos/uso terapêutico , Síndrome de Exfoliação/tratamento farmacológico , Glaucoma de Ângulo Aberto/tratamento farmacológico , Prostaglandinas F Sintéticas/uso terapêutico , Timolol/uso terapêutico , Adulto , Idoso , Anti-Hipertensivos/efeitos adversos , Ritmo Circadiano/efeitos dos fármacos , Síndrome de Exfoliação/fisiopatologia , Feminino , Glaucoma de Ângulo Aberto/fisiopatologia , Humanos , Pressão Intraocular/efeitos dos fármacos , Latanoprosta , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Prostaglandinas F Sintéticas/efeitos adversos , Método Simples-Cego , Timolol/efeitos adversos
4.
J Glaucoma ; 10(4): 316-24, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11558817

RESUMO

PURPOSE: To compare the intraocular pressure-lowering effect of latanoprost with that of dorzolamide when added to timolol. PATIENTS AND METHODS: This randomized, open-label study with two parallel groups was conducted in five centers in Greece. The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma (intraocular pressure of at least 22 mm Hg) or ocular hypertension (intraocular pressure of at least 27 mm Hg) who were receiving monotherapy with a beta-blocker or dual therapy in which one of the agents was a beta-blocker. The patients were switched to timolol 0.5% twice daily for 2 to 4 weeks (run-in period) before the start of the study (baseline). At baseline, the patients were randomized to receive latanoprost 0.005% once daily or dorzolamide 2% twice daily as add-on therapy to timolol. The intraocular pressure was recorded at 9:30 AM, 12:30 PM, and 3:30 PM at baseline and at 3 months. Safety was followed throughout the study. RESULTS: The diurnal intraocular pressure reduction was significant in both groups (P < 0.001). The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group. The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001). Drugs administered in both treatment groups were well tolerated. CONCLUSION: This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.


Assuntos
Anti-Hipertensivos/uso terapêutico , Glaucoma de Ângulo Aberto/tratamento farmacológico , Pressão Intraocular/efeitos dos fármacos , Prostaglandinas F Sintéticas/uso terapêutico , Sulfonamidas/uso terapêutico , Tiofenos/uso terapêutico , Timolol/uso terapêutico , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Inibidores da Anidrase Carbônica/uso terapêutico , Sinergismo Farmacológico , Quimioterapia Combinada , Feminino , Grécia , Humanos , Latanoprosta , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/tratamento farmacológico , Soluções Oftálmicas
5.
Ophthalmology ; 108(3): 599-604, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11237916

RESUMO

OBJECTIVE: To determine the frequency of Helicobacter pylori (H. pylori) infection in glaucoma patients and in anemic control participants. DESIGN: Prospective, nonrandomized, comparative study. PARTICIPANTS: The authors investigated 32 patients with chronic open-angle glaucoma (COAG), 9 patients with pseudoexfoliation glaucoma (PEG), and 30 age-matched anemic control participants. METHODS: Upper gastrointestinal endoscopy was performed to evaluate macroscopic abnormalities, and gastric mucosal biopsy specimens were obtained for the presence of H. pylori infection tested by rapid urease slide test (CLO test) and by Cresyl fast violet staining, Giemsa staining, or both. The presence of gastritis was classified in accordance with the Sydney system by using hematoxylin and eosin stain. In addition, intestinal metaplasia was evaluated with Alcian blue stain. Saliva samples were also tested by CLO. Serum was analyzed for the presence of H. pylori-specific IgG antibodies by enzyme-linked immunosorbent assay. MAIN OUTCOME MEASURE: Histologic examination for the presence of H. pylori. RESULTS: In 87.5% of the COAG patients, 88.9% of the PEG patients, and 46.7% of the anemic control participants, H. pylori infection was histologically confirmed (odds ratio, 8.00; chi-square, 11.81; P = 0.0006 and 9.14; chi-square, 5.01; P = 0.02, respectively). H. pylori was detected by urease test: (1) in the gastric mucosa in 71.9% of the COAG patients, in 77.8% of the PEG patients, and in 46.7% of the anemic control participants (P = 0.03 and P > 0.05, respectively); and (2) in the saliva in 37.5% of the COAG patients, in 55.6% of the PEG patients, and in 30% of the anemic control participants (P > 0.05). Sixty-eight percent of glaucoma patients and 30% of anemic control participants were seropositive for H. pylori (P = 0.002). When compared with anemic control participants, glaucoma patients exhibited less often endoscopic normal appearance of gastric mucosa (P = 0.01), and more often antral gastritis (P = 0.0004) or peptic ulcer disease (P = 0.01). Histologic grade 3 gastritis was observed only in the glaucoma patients (P = 0.03). CONCLUSIONS: H. pylori infection seems more frequent in glaucoma patients. If confirmed, this may indicate either a common factor that causes susceptibilities to both glaucoma and H. pylori infection or that H. pylori may be a causal factor for developing glaucoma.


Assuntos
Glaucoma de Ângulo Aberto/complicações , Infecções por Helicobacter/complicações , Helicobacter pylori/isolamento & purificação , Adulto , Idoso , Anticorpos Antibacterianos/sangue , Doença Crônica , Endoscopia Gastrointestinal , Ensaio de Imunoadsorção Enzimática , Síndrome de Exfoliação/complicações , Síndrome de Exfoliação/tratamento farmacológico , Feminino , Mucosa Gástrica/microbiologia , Mucosa Gástrica/patologia , Gastrite/diagnóstico , Gastrite/microbiologia , Glaucoma de Ângulo Aberto/tratamento farmacológico , Infecções por Helicobacter/diagnóstico , Helicobacter pylori/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...